What to Look for When Selecting a Nanoparticle CDMO Partner

Selecting a nanoparticle CDMO is an early technical decision with long-term consequences. A partner that can produce a promising development batch may still struggle when the process has to scale, specifications tighten, or quality requirements increase.

Nanoparticle processes are especially sensitive to those transitions. Changes in mixing, purification, surface chemistry, concentration, or handling can affect particle size, morphology, aggregation, and ultimately product performance. The right CDMO should understand the material and know how to manufacture it reproducibly as your program advances.

Look for Depth in Nanoparticle Development

Nanoparticle manufacturing brings challenges that general chemical or pharmaceutical processing experience may not fully address. Colloidal stability, nucleation and growth, surface chemistry, functionalization, purification, and storage conditions can all influence the finished material.

Ask what types of particles the team has worked with, which properties they routinely control, and how they troubleshoot changes in performance. Experience across different compositions, sizes, morphologies, and surface chemistries gives a development team a broader base for solving new problems.

For programs still defining the particle itself, custom nanoparticle development capabilities are also important. Your CDMO should be able to connect particle design decisions to manufacturability from the start.

Ask How They Approach Scale-Up

Scaling a nanoparticle process involves more than increasing batch volume. Mixing, addition rates, reaction kinetics, heat transfer, filtration, concentration, and purification can all behave differently as production grows.

A strong CDMO should be able to explain how it identifies critical process parameters, evaluates scale-dependent risks, and confirms that material properties remain consistent as the process changes. Previous experience moving nanoparticle processes from the bench through pilot and manufacturing scale is particularly valuable.

Look for process development and manufacturing teams that work together early. Scale-up becomes much easier when manufacturability is considered before the formulation and process have been locked down.

Look at Manufacturing and Characterization Together

An equipment list tells you what a facility owns. A better question is how well its manufacturing and analytical capabilities work together.

During development and scale-up, the team should be able to change a process and quickly determine how that change affected particle size, morphology, surface properties, concentration, purity, or another critical attribute. In-house access to techniques such as TEM, SEM, DLS, zeta potential, UV-Vis, ICP-MS, chromatography, and application-specific testing can shorten that feedback loop.

Explore our nanoparticle characterization guides and protocols for examples of analytical methods commonly used to evaluate nanoparticle properties.

Evaluate the Quality System Early

Quality requirements usually increase as a program moves toward regulated or commercial use. Documentation, traceability, change control, batch records, testing, and release requirements can become much more important later in development.

Review the CDMO's quality systems before you need those controls. Ask which activities fall within certified systems, what additional controls can be incorporated for your program, and how documentation evolves as manufacturing advances.

Consider BIOSECURE Compliance and Supply-Chain Visibility

Manufacturing location and supplier dependencies have become part of biotechnology supplier qualification. Ask where synthesis, purification, surface modification, characterization, and other critical steps take place. Find out which activities depend on subcontractors and whether important raw materials or services create additional supply-chain exposure.

The BIOSECURE Act adds another consideration, particularly for organizations involved in federal contracts, grants, or loans. When relevant to your program, ask prospective suppliers and CDMOs about BIOSECURE Act compliance and how their manufacturing network aligns with your procurement requirements.

A U.S. sales office alone doesn't tell you where critical work happens. Understanding where your material is actually developed, manufactured, and tested gives procurement and technical teams a clearer view of supply-chain risk.

Choose With the Next Stage in Mind

A supplier change becomes more difficult once a nanoparticle is embedded in a formulation, assay, device, or established manufacturing process. Requalification can require new characterization, comparability testing, process transfer, and documentation.

Before starting development, ask how far the CDMO can take the program. Ideally, the same organization can support feasibility, optimization, scale-up, analytical work, and routine manufacturing while preserving the technical knowledge developed along the way.

Nanoparticle Development and Manufacturing at nanoComposix

nanoComposix has developed and manufactured engineered nanoparticles since 2004. Our San Diego team supports programs from early feasibility through process development and manufacturing.

nanoComposix is BIOSECURE Act compliant, with products and custom solutions developed and manufactured in San Diego, California. Our R&D and Manufacturing Science & Technology teams collaborate across development so that scale-up considerations can be addressed early.

Our facility combines nanoparticle manufacturing with extensive in-house characterization, supported by an ISO 13485:2016-certified quality management system, FDA Drug Establishment Registration, and a State of California Drug Manufacturing License supporting applicable regulated manufacturing programs.